Cargando…
Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including wha...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511655/ https://www.ncbi.nlm.nih.gov/pubmed/36137649 http://dx.doi.org/10.1136/jitc-2022-004902 |
_version_ | 1784797686026731520 |
---|---|
author | Volpe, Alessia Adusumilli, Prasad S Schöder, Heiko Ponomarev, Vladimir |
author_facet | Volpe, Alessia Adusumilli, Prasad S Schöder, Heiko Ponomarev, Vladimir |
author_sort | Volpe, Alessia |
collection | PubMed |
description | Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice. |
format | Online Article Text |
id | pubmed-9511655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-95116552022-09-27 Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients Volpe, Alessia Adusumilli, Prasad S Schöder, Heiko Ponomarev, Vladimir J Immunother Cancer Review Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice. BMJ Publishing Group 2022-09-22 /pmc/articles/PMC9511655/ /pubmed/36137649 http://dx.doi.org/10.1136/jitc-2022-004902 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Volpe, Alessia Adusumilli, Prasad S Schöder, Heiko Ponomarev, Vladimir Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title | Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title_full | Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title_fullStr | Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title_full_unstemmed | Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title_short | Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
title_sort | imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511655/ https://www.ncbi.nlm.nih.gov/pubmed/36137649 http://dx.doi.org/10.1136/jitc-2022-004902 |
work_keys_str_mv | AT volpealessia imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients AT adusumilliprasads imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients AT schoderheiko imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients AT ponomarevvladimir imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients |